Skip to content

Author

Si-Jia Yan

We have 3 of 19 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Advances in CAR-T and CAR-NK cell therapy in follicular lymphoma: a review.

Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma and is characterized by prolonged survival but recurrent relapses. The unmet need is greatest among patients with high-risk disease, including progression of disease within 24 months of first-line immunochemotherapy (POD24), double-refract...

Si-Jia Yan, Wan-Ying Liu, Mi Zhou et al. · 0 citations
Review Open access Sep 2026

Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.

BACKGROUND B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can induce deep responses in relapsed or refractory multiple myeloma, yet relapse remains frequent. Neither post-infusion maintenance nor salvage after CAR T-cell failure has an established standard. MAIN TEXT This rev...

Shuai-Xi Su, Si-Jia Yan, Jia-Ying Wu et al. · 0 citations
Sep 2026

Exosomal METTL16 from mesenchymal stem cells promotes malignant progression and M2 macrophage polarization in acute myeloid leukemia via IGF2BP2-dependent GPX1 m6A modification.

Exosomal METTL16 from AML-MSCs plays a crucial role in promoting leukemic cell survival and M2 polarization, and targeting this axis may provide a potential theoretical foundation to reverse M2 macrophage polarization and inhibit AML progression.

Zhen Shang, Mi Zhou, Si-Jia Yan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.